# A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）

> **NCT03137368** · PHASE3 · UNKNOWN · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 300 (estimated)

## Conditions studied

- CYP2D6 Polymorphism

## Interventions

- **DRUG:** Exemestane Tablets
- **OTHER:** ovarian function suppression/ablation
- **GENETIC:** CYP2D6*10 gene test
- **DRUG:** Tamoxifen

## Key facts

- **NCT ID:** NCT03137368
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-09
- **Primary completion:** 2023-10-30
- **Final completion:** 2023-10-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2018-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03137368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03137368, "A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03137368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*